---
title: "Clonazepam - Complete Profile"
substance: "Clonazepam"
chemical_name: "5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one"
category: "Depressant"
legal_status: "Schedule IV (US), Prescription Only"
description: "The anticonvulsant king - potent long-acting benzodiazepine with exceptional seizure control and anxiety relief"
permalink: "/dyos-domain/substances/clonazepam/"
---

<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> 竊・<a href="/dyos-domain/depressants/">Depressants</a> 竊・<span>Clonazepam</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>汳 Clonazepam</h1>
        <h2 class="chemical-name">5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one</h2>
         <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Clonazepam" 
                data-category="Depressants" 
                data-chemical="5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Klonopin</span> 窶｢ <span>Rivotril</span> 窶｢ <span>Clonotril</span> 窶｢ <span>Iktorivil</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>K-pins</span> 窶｢ <span>Klonnies</span> 窶｢ <span>Super Valium</span> 窶｢ <span>Pin</span>
            </div>
            <div class="name-category">
              <h4>Generic Names</h4>
              <span>Clonazepam</span> 窶｢ <span>Clonazepamum</span> 窶｢ <span>Ro 5-4023</span>
            </div>
            <div class="name-category">
              <h4>Medical Abbreviations</h4>
              <span>CZP</span> 窶｢ <span>CLNZ</span> 窶｢ <span>7-Nitro-clonazepam</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status schedule-4">Schedule IV</span>
          <span class="duration long">18-50 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="{{ '/assets/substances/clonazepam.jpg' | url }}" alt="Clonazepam tablets and molecular structure" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>洫ｬ C竄≫ｅH竄≫・ClN竄グ竄・/p>
            <p>MW: 315.71 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>沐 Physical Identification</h3>
      <div class="identification-info">
        <div class="pharmaceutical-forms">
          <h4>Pharmaceutical Tablets</h4>
          <ul>
            <li><strong>0.5mg:</strong> Orange, round, scored tablets (Teva: orange oval)</li>
            <li><strong>1mg:</strong> Blue, round, scored tablets (generic varies)</li>
            <li><strong>2mg:</strong> White, round, scored tablets (some yellow)</li>
            <li><strong>Markings:</strong> Various imprints (TEVA, C1, C2, etc.)</li>
            <li><strong>Texture:</strong> Hard pressed tablets, some with score lines</li>
          </ul>
        </div>
        
        <div class="pure-form">
          <h4>Pure Clonazepam</h4>
          <ul>
            <li><strong>Appearance:</strong> Light yellow to yellow crystalline powder</li>
            <li><strong>Odor:</strong> Practically odorless</li>
            <li><strong>Taste:</strong> Bitter metallic taste</li>
            <li><strong>Solubility:</strong> Slightly soluble in water, soluble in acetone</li>
            <li><strong>Melting point:</strong> 236-238ﾂｰC</li>
            <li><strong>Stability:</strong> Light sensitive, store in dark containers</li>
          </ul>
        </div>
        
        <div class="disintegrating-tablets">
          <h4>Orally Disintegrating Tablets (ODT)</h4>
          <ul>
            <li><strong>0.125mg, 0.25mg, 0.5mg, 1mg, 2mg:</strong> Available strengths</li>
            <li><strong>Appearance:</strong> White to off-white, rapidly dissolving</li>
            <li><strong>Taste:</strong> Mint flavor to mask bitterness</li>
            <li><strong>Dissolution:</strong> Dissolves in seconds on tongue</li>
          </ul>
        </div>
        
        <div class="identification-tests">
          <h4>洫ｪ Identification Tests</h4>
          <ul>
            <li><strong>UV spectroscopy:</strong> ﾎｻmax at 230nm, 280nm, 309nm</li>
            <li><strong>IR spectroscopy:</strong> C=O stretch at 1680 cm竅ｻﾂｹ</li>
            <li><strong>LC-MS/MS:</strong> Molecular ion [M+H]+ at m/z 316</li>
            <li><strong>Color tests:</strong> Positive with Liebermann reagent</li>
          </ul>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>汳 Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">0.125-0.25mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">0.25-0.5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">0.5-1mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">1-2mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">2mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Medical Dosing Guidelines</h4>
        <ul>
          <li><strong>Panic disorder:</strong> 0.25mg BID, increase to 1mg daily</li>
          <li><strong>Seizure disorders:</strong> 1.5mg daily in 3 divided doses</li>
          <li><strong>Maximum daily:</strong> 4mg for seizures, 2mg for anxiety</li>
          <li><strong>Elderly patients:</strong> Start with 0.25mg daily, increase slowly</li>
          <li><strong>Onset:</strong> 20-60 minutes oral</li>
          <li><strong>Peak effects:</strong> 1-4 hours</li>
        </ul>
      </div>
      
      <div class="special-populations">
        <h4>Special Population Dosing</h4>
        <ul>
          <li><strong>Pediatric seizures:</strong> 0.01-0.03mg/kg/day initially</li>
          <li><strong>Hepatic impairment:</strong> Reduce dose by 50%</li>
          <li><strong>Renal impairment:</strong> No adjustment typically needed</li>
          <li><strong>Geriatric:</strong> Start 0.125mg daily, titrate slowly</li>
        </ul>
      </div>
      
      <div class="tapering-warning">
        <h4>泅ｨ Withdrawal Tapering</h4>
        <p><strong>Critical:</strong> Never stop abruptly - life-threatening seizures possible</p>
        <p><strong>Tapering:</strong> Reduce by 0.125-0.25mg every 1-2 weeks</p>
        <p><strong>Long-term use:</strong> May require months of gradual reduction</p>
      </div>
      
      <p class="dosage-note"><strong>Warning:</strong> Extremely potent benzodiazepine - 0.5mg clonazepam 竕・10mg diazepam. Start low, titrate slowly.</p>
    </div>

    <div class="profile-section effects">
      <h3>笨ｨ Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:20-1:00</span>
          <span class="effect">Onset - subtle anxiety relief, mild sedation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-4:00</span>
          <span class="effect">Peak - maximum anxiolytic and anticonvulsant effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-24:00</span>
          <span class="effect">Plateau - sustained therapeutic effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+24:00-72:00</span>
          <span class="effect">Decline - gradual return to baseline</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category therapeutic">
          <h4>笨・Therapeutic Effects</h4>
          <ul>
            <li>Powerful anxiety reduction</li>
            <li>Excellent seizure prevention</li>
            <li>Muscle relaxation and spasm relief</li>
            <li>Panic attack termination</li>
            <li>Sleep induction and maintenance</li>
            <li>Mood stabilization</li>
            <li>Reduced agoraphobia symptoms</li>
          </ul>
        </div>
        
        <div class="effect-category adverse">
          <h4>笶・Side Effects</h4>
          <ul>
            <li>Drowsiness and fatigue</li>
            <li>Coordination problems (ataxia)</li>
            <li>Memory impairment</li>
            <li>Confusion, "brain fog"</li>
            <li>Depression and mood changes</li>
            <li>Paradoxical disinhibition</li>
            <li>Cognitive slowing</li>
            <li>Physical dependence</li>
          </ul>
        </div>
      </div>

      <div class="unique-effects">
        <h4>沁ｯ Unique Characteristics</h4>
        <div class="characteristic-items">
          <div class="characteristic">
            <h5>Anticonvulsant Superiority</h5>
            <p>One of the most potent anticonvulsants in the benzodiazepine class, effective against all seizure types including status epilepticus.</p>
          </div>
          <div class="characteristic">
            <h5>Long Duration</h5>
            <p>Extremely long half-life (18-50 hours) provides sustained effects but increases accumulation risk with daily dosing.</p>
          </div>
          <div class="characteristic">
            <h5>High Potency</h5>
            <p>20x more potent than diazepam - small doses produce significant effects, making precise dosing critical.</p>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>洫 Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Clonazepam enhances GABAergic inhibition by binding to the benzodiazepine site on GABA-A receptors. The nitro group at position 7 and chlorine substitution increase receptor affinity and anticonvulsant activity compared to other benzodiazepines. It particularly targets ﾎｱ1, ﾎｱ2, and ﾎｱ5-containing GABA-A receptor subtypes.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A (ﾎｱ1ﾎｲ2ﾎｳ2)</strong></span>
            <span class="affinity">Very high affinity (Ki: 0.7 nM)</span>
            <span class="function">Sedation, amnesia, muscle relaxation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A (ﾎｱ2ﾎｲ2ﾎｳ2)</strong></span>
            <span class="affinity">High affinity (Ki: 1.2 nM)</span>
            <span class="function">Anxiolytic effects, anticonvulsant activity</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A (ﾎｱ3ﾎｲ2ﾎｳ2)</strong></span>
            <span class="affinity">Moderate affinity (Ki: 3.1 nM)</span>
            <span class="function">Muscle relaxation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A (ﾎｱ5ﾎｲ2ﾎｳ2)</strong></span>
            <span class="affinity">High affinity (Ki: 1.0 nM)</span>
            <span class="function">Memory impairment, cognitive effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Serotonin 5-HT2A</strong></span>
            <span class="affinity">Weak antagonism</span>
            <span class="function">May contribute to mood effects</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary pathway:</strong> Nitro reduction to 7-aminoclonazepam by cytoplasmic nitroreductases</p>
          <p><strong>Secondary pathway:</strong> N-acetylation to 7-acetamidoclonazepam (inactive)</p>
          <p><strong>Minor pathway:</strong> 3-hydroxylation by CYP3A4</p>
          <p><strong>Half-life:</strong> 18-50 hours (average 30-40 hours)</p>
          <p><strong>Bioavailability:</strong> 85-90% oral absorption</p>
          <p><strong>Peak plasma:</strong> 1-4 hours</p>
          <p><strong>Protein binding:</strong> 85% bound to albumin</p>
          <p><strong>Active metabolites:</strong> 7-aminoclonazepam (weak activity)</p>
        </div>

        <h4>Unique Pharmacological Features</h4>
        <ul>
          <li><strong>Nitro group:</strong> Confers superior anticonvulsant properties</li>
          <li><strong>High CNS penetration:</strong> Rapidly crosses blood-brain barrier</li>
          <li><strong>Long half-life:</strong> Allows once or twice daily dosing</li>
          <li><strong>Low abuse potential:</strong> Relative to other benzodiazepines</li>
          <li><strong>Tolerance profile:</strong> Anticonvulsant tolerance develops slower than sedative tolerance</li>
          <li><strong>Withdrawal severity:</strong> Particularly dangerous due to long half-life and high potency</li>
        </ul>

        <h4>Seizure Mechanism</h4>
        <p>Clonazepam's exceptional anticonvulsant activity stems from its ability to enhance tonic GABA inhibition in key seizure circuits. The nitro substitution increases binding affinity to synaptic and extrasynaptic GABA-A receptors in the thalamus, cortex, and hippocampus - critical areas for seizure generation and propagation.</p>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>笞・・Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>泅ｨ Critical Warnings</h4>
          <ul>
            <li><strong>Withdrawal seizures:</strong> Life-threatening if stopped abruptly</li>
            <li><strong>Respiratory depression:</strong> Especially with alcohol/opioids</li>
            <li><strong>Physical dependence:</strong> Develops within 2-4 weeks</li>
            <li><strong>Cognitive impairment:</strong> Significant memory and learning deficits</li>
            <li><strong>Falls risk:</strong> Muscle weakness and ataxia in elderly</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>泝｡・・Essential Precautions</h4>
          <ul>
            <li>Never stop suddenly - taper under medical supervision</li>
            <li>Avoid alcohol and other CNS depressants</li>
            <li>Don't drive or operate machinery</li>
            <li>Store securely away from children</li>
            <li>Take exactly as prescribed - no dose adjustments</li>
            <li>Regular medical monitoring for long-term use</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>泅ｫ Absolute Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Severe respiratory insufficiency, sleep apnea, myasthenia gravis, severe liver disease, or known benzodiazepine hypersensitivity.</p>
      </div>

      <div class="withdrawal-syndrome">
        <h4>沐･ Withdrawal Syndrome</h4>
        <div class="withdrawal-symptoms">
          <p><strong>Early (1-4 days):</strong> Anxiety, insomnia, tremor, sweating</p>
          <p><strong>Peak (5-14 days):</strong> Seizures, hallucinations, delirium, hyperthermia</p>
          <p><strong>Protracted (weeks-months):</strong> Depression, anxiety, cognitive issues</p>
          <p><strong>Medical emergency:</strong> Grand mal seizures can be fatal</p>
        </div>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>笞暦ｸ・Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>沐ｴ Dangerous</h4>
          <ul>
            <li><strong>Alcohol:</strong> Severe CNS depression, respiratory arrest</li>
            <li><strong>Opioids:</strong> Fatal respiratory depression risk</li>
            <li><strong>Barbiturates:</strong> Additive CNS depression</li>
            <li><strong>Other benzodiazepines:</strong> Overdose risk</li>
            <li><strong>Muscle relaxants:</strong> Excessive sedation</li>
          </ul>
        </div>
        
        <div class="interaction significant">
          <h4>沺｡ Significant Risk</h4>
          <ul>
            <li><strong>CYP3A4 inhibitors:</strong> Ketoconazole, ritonavir increase levels</li>
            <li><strong>Anticonvulsants:</strong> Phenytoin, carbamazepine may reduce efficacy</li>
            <li><strong>Sedating antihistamines:</strong> Enhanced drowsiness</li>
            <li><strong>Antipsychotics:</strong> Increased sedation and confusion</li>
          </ul>
        </div>
        
        <div class="interaction moderate">
          <h4>沺 Moderate Risk</h4>
          <ul>
            <li><strong>Rifampin:</strong> May reduce clonazepam levels</li>
            <li><strong>Fluoxetine:</strong> May increase clonazepam levels slightly</li>
            <li><strong>Omeprazole:</strong> Minor increase in clonazepam levels</li>
            <li><strong>Grapefruit juice:</strong> Slight increase in absorption</li>
          </ul>
        </div>
      </div>

      <div class="special-interactions">
        <h4>笞・・Special Interaction Warnings</h4>
        <div class="interaction-warning">
          <h5>Opioid Crisis Connection</h5>
          <p>The combination of clonazepam with opioids has become a major contributor to overdose deaths. Even therapeutic doses can be fatal when combined.</p>
        </div>
        <div class="interaction-warning">
          <h5>Polydrug Withdrawal</h5>
          <p>Patients on both clonazepam and other substances require specialized medical detoxification protocols to prevent multiple withdrawal syndromes.</p>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>笞厄ｸ・Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>氈E氈E United States</h4>
            <p><strong>Schedule IV</strong> - Controlled substance with accepted medical use. Prescription required with refill limitations. DEA tracking for prescribers.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E United Kingdom</h4>
            <p><strong>Class C</strong> - Prescription only medicine (POM). Illegal to possess without prescription. Maximum 2 years imprisonment for supply.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E Canada</h4>
            <p><strong>Schedule IV</strong> - Prescription required. Controlled under Controlled Drugs and Substances Act.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E Australia</h4>
            <p><strong>Schedule 4</strong> - Prescription only medicine with additional restrictions on quantity and repeats.</p>
          </div>
        </div>
        
        <div class="prescription-monitoring">
          <h4>沒 Prescription Monitoring</h4>
          <p>Subject to prescription drug monitoring programs (PDMPs) in most jurisdictions due to abuse potential and dangerous withdrawal syndrome. Prescribers must check databases before prescribing.</p>
        </div>

        <div class="medical-guidelines">
          <h4>沛･ Medical Guidelines</h4>
          <ul>
            <li><strong>Seizure disorders:</strong> First-line for certain epilepsy types</li>
            <li><strong>Panic disorder:</strong> FDA-approved indication</li>
            <li><strong>Off-label uses:</strong> Bipolar disorder, tardive dyskinesia, REM sleep behavior disorder</li>
            <li><strong>Duration limits:</strong> Long-term use requires regular reassessment</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>沒 History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1964</span>
          <p>Synthesized by Leo Sternbach at Hoffmann-La Roche</p>
        </div>
        <div class="history-event">
          <span class="year">1967</span>
          <p>First clinical trials for epilepsy at Roche</p>
        </div>
        <div class="history-event">
          <span class="year">1973</span>
          <p>FDA approval for seizure disorders as Klonopin</p>
        </div>
        <div class="history-event">
          <span class="year">1982</span>
          <p>European approval as Rivotril for broader indications</p>
        </div>
        <div class="history-event">
          <span class="year">1994</span>
          <p>FDA approval for panic disorder</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Generic versions become widely available</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Increased scrutiny due to benzodiazepine crisis</p>
        </div>
      </div>

      <div class="medical-evolution">
        <h4>Medical Evolution</h4>
        <p>Clonazepam represented a major advance in epilepsy treatment, providing superior seizure control with less sedation than barbiturates. However, its role has evolved from broad anxiety treatment to more targeted use due to dependency concerns and the development of alternative medications.</p>
      </div>

      <div class="cultural-impact">
        <h4>Cultural & Social Impact</h4>
        <p>Unlike other benzodiazepines, clonazepam gained less recreational notoriety due to its long duration and subtle effects. However, it became associated with chronic anxiety management and the broader "benzodiazepine epidemic" of the 2000s-2010s, leading to increased awareness of iatrogenic dependence.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>沐ｬ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Epilepsy Optimization</h4>
          <p>Research into personalized dosing based on genetic factors affecting metabolism, and combination therapies for treatment-resistant epilepsy.</p>
        </div>
        
        <div class="research-item">
          <h4>Withdrawal Protocols</h4>
          <p>Development of safer, more comfortable withdrawal protocols including micro-tapering and adjunctive medications to ease discontinuation.</p>
        </div>
        
        <div class="research-item">
          <h4>REM Sleep Behavior Disorder</h4>
          <p>Expanding research into clonazepam's unique efficacy for REM sleep behavior disorder, particularly in Parkinson's disease and Lewy body dementia.</p>
        </div>
        
        <div class="research-item">
          <h4>Bipolar Disorder</h4>
          <p>Investigation of clonazepam's role in bipolar disorder management, both for acute episodes and maintenance therapy.</p>
        </div>

        <div class="research-item">
          <h4>Neuroprotection</h4>
          <p>Studies examining whether clonazepam's anticonvulsant properties provide neuroprotective benefits in neurodegenerative diseases.</p>
        </div>
      </div>

      <div class="future-directions">
        <h4>Future Research Directions</h4>
        <ul>
          <li><strong>Subtype-selective drugs:</strong> Development of GABA-A receptor subtype-selective compounds</li>
          <li><strong>Biomarkers:</strong> Identifying predictors of response and withdrawal severity</li>
          <li><strong>Alternative delivery:</strong> Long-acting formulations and alternative routes</li>
          <li><strong>Combination therapies:</strong> Optimal combinations with newer anticonvulsants</li>
        </ul>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>沒 Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.epilepsy.com/">Epilepsy Foundation</a> - Seizure disorder information</li>
          <li><a href="https://www.drugs.com/klonopin.html">Drugs.com</a> - Comprehensive drug information</li>
          <li><a href="https://dailymed.nlm.nih.gov/">DailyMed</a> - FDA-approved prescribing information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Withdrawal Support</h4>
        <ul>
          <li><a href="https://www.benzoinfo.com/">Benzodiazepine Information Coalition</a> - Withdrawal resources</li>
          <li><a href="https://www.benzosupport.org/">Benzo Support</a> - Community support forums</li>
          <li><a href="https://w-bad.org/">Withdrawal and Dependence</a> - Medical withdrawal information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Professional Resources</h4>
        <ul>
          <li><a href="https://www.aan.com/">American Academy of Neurology</a> - Professional guidelines</li>
          <li><a href="https://www.psychiatry.org/">American Psychiatric Association</a> - Treatment guidelines</li>
          <li><a href="https://www.deadiversion.usdoj.gov/">DEA Diversion Control</a> - Regulatory information</li>
        </ul>
      </div>
    </div>
  </div>

</div>

